132475-60-6

Basic information

• Product Name: 2-BROMO-N-HYDROXY-BENZAMIDINE
• Synonyms: 2-BROMO-N-HYDROXY-BENZAMIDINE;2-BROMO-N-HYDROXYBENZIMIDAMIDE;Benzenecarboximidamide,2-bromo-N-hydroxy-
• CAS NO: 132475-60-6
• Molecular Formula: C₇H₇BrN₂O
• Molecular Weight: 215.05
• Mol File: 132475-60-6.mol

Chemical Properties

• Boiling Point: 367.2 °C at 760 mmHg
• Flash Point: 175.9 °C
• Appearance: /
• Density: 1.68 g/cm³
• CAS DataBase Reference: 2-BROMO-N-HYDROXY-BENZAMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-N-HYDROXY-BENZAMIDINE(132475-60-6)
• EPA Substance Registry System: 2-BROMO-N-HYDROXY-BENZAMIDINE(132475-60-6)

Safety Data

• Hazardous Substances Data: 132475-60-6(Hazardous Substances Data)

Usage

Uses

Used in Biological Research:
2-BROMO-N-HYDROXY-BENZAMIDINE is used as an enzyme inhibitor for studying proteases and other enzymes. Its ability to selectively inhibit specific enzymes makes it a crucial tool in understanding various biochemical processes.
Used in Pharmaceutical Development:
2-BROMO-N-HYDROXY-BENZAMIDINE is used as a reagent in the development of new drugs. Its structure and properties contribute to the advancement of pharmaceuticals targeting specific medical conditions.
Used in Synthesis of Pharmaceuticals:
2-BROMO-N-HYDROXY-BENZAMIDINE is used as a key component in the synthesis of pharmaceuticals, playing a role in the creation of new treatments for various medical conditions.
Used in Medical Treatments:
2-BROMO-N-HYDROXY-BENZAMIDINE has potential applications in the treatment of various medical conditions, thanks to its role in enzyme inhibition and pharmaceutical development.

Upstream product

• 2042-37-7 o-cyanobromobenzene 
• 6630-33-7 ortho-bromobenzaldehyde 
• 34158-72-0 2-bromobenzaldehyde oxime 

Downstream Products

• 110703-55-4 {3-[3-(2-Bromo-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-4-oxo-3,4-dihydro-phthalazin-1-yl}-acetic acid 
• 110722-39-9 {3-[3-(2-Bromo-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-4-oxo-3,4-dihydro-phthalazin-1-yl}-acetic acid ethyl ester 
• 90224-62-7 3-(2-bromo-phenyl)-5-chloromethyl-[1,2,4]oxadiazole 
• 132293-60-8 SbCl₅N(OH)C(NH₂)C₆H₄Br 
• 1430424-10-4 C₂₁H₁₉BrClN₃O₂ 
• 343269-59-0 N-(2-bromophenyl)cyanamide 

Relevant articles and documents

Cobalt-Catalyzed, Directed Intermolecular C-H Bond Functionalization for Multiheteroatom Heterocycle Synthesis: The Case of Benzotriazine

Transition-metal-catalyzed, directed intermolecular C-H bond functionalization is synthetically useful but heavily underexplored in multiheteroatom heterocycle synthesis. Herein we report a cobalt catalytic method for the formation of a three-nitrogen-bearing benzotriazine scaffold via the coupling of arylhydrazine and oxadiazolone. This synthetic protocol features a low-cost base metal catalyst, a maximum number of heteroatoms built into a heterocycle, a distinct synthetic logic for benzotriazines, a superior step economy, and a broad substrate scope.

SO2F2-Mediated one-pot cascade process for transformation of aldehydes (RCHO) to cyanamides (RNHCN)

A simple, mild and practical cascade process for the direct conversion of aldehydes to cyanamides was developed featuring a wide substrate scope and great functional group tolerability. This method allows for transformations of readily available, inexpensive, and abundant aldehydes to highly valuable cyanamides in a pot, atom, and step-economical manner with a green nitrogen source. This protocol will serve as a robust tool for the installation of the cyanamide moiety in various complicated molecules.

A cascade process for directly converting nitriles (RCN) to cyanamides (RNHCN) via SO2F2-activated Tiemann rearrangement

A simple, mild and practical process for the direct conversion of nitriles to cyanamides was newly discovered and exhibited a wide substrate scope as well as great functional group-tolerability (36 examples). In this efficient strategy, the in situ generated amidoximes obtained from the reaction of nitriles with hydroxylamine subsequently underwent Tiemann rearrangement, producing the corresponding cyanamides with great isolated yields under SO2F2. Additionally, the control experiments reportedly shed light on the tentative mechanism involved in the formation and elimination of the key intermediate: a sulfonyl ester.

TiO2-Nanoparticles Catalyzed Synthesis of New Trifluoromethyl-4,5-dihydro-1,2,4-oxadiazoles and Trifluoromethyl-1,2,4-oxadiazoles

Synthesis of a new series of trifluoromethyl-4,5-dihydro-1,2,4-oxadiazoles and trifluoromethyl-1,2,4-oxadiazoles have been described by utilizing the reactions between amidoximes and trifluoroacetimidoyl chlorides. Trifluoromethyl-4,5-dihydro-1,2,4-oxadia

Structure-activity and structure-property relationships of novel Nrf2 activators with a 1,2,4-oxadiazole core and their therapeutic effects on acetaminophen (APAP)-induced acute liver injury

The antioxidant function induced by Nrf2 protects the liver from damage. We found a novel Nrf2 activator named compound 25 via structural modification of compound 1 we previously reported. In vitro, compound 25 induced Nrf2 transport into the nucleus and protected hepatocyte L02 cells from APAP-induced cytotoxicity via activating the Nrf2-ARE signaling pathway. In vivo, 25 exhibited therapeutic effects in a mouse model of acute liver injury induced by acetaminophen (APAP) by up-regulating Nrf2-dependent antioxidases and down-regulating liver injury markers in serum. Together, these results indicated that 25 is a potent Nrf2/ARE activator both in vitro and in vivo. The drug-like properties of compound 25 further revealed its potential for development as a therapeutic drug against acute liver injury.

NOVEL N-[(PYRIMIDINYLOXY)PROPANYL]BENZAMIDES

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, R2, R3, R4, R5 have meanings given in the description.

NOVEL N-[(PYRAZINYLOXY)PROPANYL]BENZAMIDES

This invention relates to compounds of formula (I) a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, Rsu

NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES

The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

NOVEL N-[(PYRIDYLOXY)PROPANYL]BENZAMIDES

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R1, Rs

Nitrobenzofurazan derivatives of N′-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1

Tryptophan metabolism through the kynurenine pathway is considered as a crucial mechanism in immune tolerance. Indoleamine 2,3-dioxygenase 1 (IDO1) plays a key role in tryptophan catabolism in the immune system and it is also considered as an important therapeutic target for the treatment of cancer and other diseases that are linked with kynurenine pathway. In this study, a series of nitrobenzofurazan derivatives of N′-hydroxybenzimidamides (1) and N′-hydroxy-2-phenylacetimidamides (2) were synthesized and their inhibitory activities against human IDO1 enzyme were tested using in-vitro and cellular enzyme activity assay. The optimization leads to the identification of potent compounds, 1d, 2i and 2k (IC50 = 39-80 nM), which are either competitive or uncompetitive inhibitors of IDO1 enzyme. These compounds also showed IDO1 inhibition potencies in the nanomolar range (IC50 = 50-71 nM) in MDA-MB-231 cells with no/negligible amount of cytotoxicity. The stronger selectivity of the potent compounds for IDO1 enzyme over tryptophan 2,3-dioxygenase (TDO) enzyme (312-1593-fold) also makes them very attractive for further immunotherapeutic applications.